These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

800 related articles for article (PubMed ID: 21257961)

  • 1. Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain.
    Mikkelsen M; Holst PJ; Bukh J; Thomsen AR; Christensen JP
    J Immunol; 2011 Feb; 186(4):2355-64. PubMed ID: 21257961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HCV-NS3 Th1 minigene vaccine based on invariant chain CLIP genetic substitution enhances CD4(+) Th1 cell responses in vivo.
    Gao M; Wang HP; Wang YN; Zhou Y; Wang QL
    Vaccine; 2006 Jun; 24(26):5491-7. PubMed ID: 16725235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel combined vaccine candidate containing epitopes of HCV NS3, core and E1 proteins induces multi-specific immune responses in BALB/c mice.
    Zeng R; Li G; Ling S; Zhang H; Yao Z; Xiu B; He F; Huang R; Wei L
    Antiviral Res; 2009 Oct; 84(1):23-30. PubMed ID: 19646486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of vaccine-induced immune responses to hepatitis C virus in rhesus macaques by altering priming before adenovirus boosting.
    Rollier C; Verschoor EJ; Paranhos-Baccala G; Drexhage JA; Verstrepen BE; Berland JL; Himoudi N; Barnfield C; Liljestrom P; Lasarte JJ; Ruiz J; Inchauspe G; Heeney JL
    J Infect Dis; 2005 Sep; 192(5):920-9. PubMed ID: 16088843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells.
    Echeverria I; Pereboev A; Silva L; Zabaleta A; Riezu-Boj JI; Bes M; Cubero M; Borras-Cuesta F; Lasarte JJ; Esteban JI; Prieto J; Sarobe P
    Hepatology; 2011 Jul; 54(1):28-37. PubMed ID: 21452282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective vaccination with hepatitis C virus NS3 but not core antigen in a novel mouse challenge model.
    El-Gogo S; Staib C; Lasarte JJ; Sutter G; Adler H
    J Gene Med; 2008 Feb; 10(2):177-86. PubMed ID: 18076128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40.
    Zabaleta A; Arribillaga L; Llopiz D; Dotor J; Lasarte JJ; Prieto J; Borrás-Cuesta F; Esteban JI; Quer J; Vayreda F; Sarobe P
    Antiviral Res; 2007 Apr; 74(1):25-35. PubMed ID: 17275104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA prime-canarypox boost with polycistronic hepatitis C virus (HCV) genes generates potent immune responses to HCV structural and nonstructural proteins.
    Pancholi P; Liu Q; Tricoche N; Zhang P; Perkus ME; Prince AM
    J Infect Dis; 2000 Jul; 182(1):18-27. PubMed ID: 10882577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins.
    Haller AA; Lauer GM; King TH; Kemmler C; Fiolkoski V; Lu Y; Bellgrau D; Rodell TC; Apelian D; Franzusoff A; Duke RC
    Vaccine; 2007 Feb; 25(8):1452-63. PubMed ID: 17098335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic immunization and comprehensive screening approaches in HLA-A2 transgenic mice lead to the identification of three novel epitopes in hepatitis C virus NS3 antigen.
    Martin P; Parroche P; Chatel L; Barretto C; Beck A; Trépo C; Bain C; Lone YC; Inchauspé G; Fournillier A
    J Med Virol; 2004 Nov; 74(3):397-405. PubMed ID: 15368525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4+ TH1 cells generated by Ii-PADRE DNA at prime phase are important to induce effectors and memory CD8+ T cells.
    Park JY; Jin DH; Lee CM; Jang MJ; Lee SY; Shin HS; Chung YH; Kim KY; Kim SS; Lee WB; Shin YK; Lee WJ; Park YM; Kim D
    J Immunother; 2010 Jun; 33(5):510-22. PubMed ID: 20463596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus.
    Arribillaga L; de Cerio AL; Sarobe P; Casares N; Gorraiz M; Vales A; Bruna-Romero O; Borrás-Cuesta F; Paranhos-Baccala G; Prieto J; Ruiz J; Lasarte JJ
    Vaccine; 2002 Dec; 21(3-4):202-10. PubMed ID: 12450695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The combined application of nucleotide and amino acid sequences of NS3 hepatitis C virus protein, DNA encoding granulocyte macrophage colony-stimulating factor and inhibitor of regulatory T cells induces effective immune response against hepatitis C virus].
    Masalova OV; Lesnova EI; Shingarova LN; Tunitskaia VL; Ulanova TI; Burkov AN; Kushch AA
    Mol Biol (Mosk); 2012; 46(3):525-34. PubMed ID: 22888642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene.
    Frelin L; Ahlén G; Alheim M; Weiland O; Barnfield C; Liljeström P; Sällberg M
    Gene Ther; 2004 Mar; 11(6):522-33. PubMed ID: 14999224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positive selection of cytotoxic T lymphocyte escape variants during acute hepatitis C virus infection.
    Guglietta S; Garbuglia AR; Pacciani V; Scottà C; Perrone MP; Laurenti L; Spada E; Mele A; Capobianchi MR; Taliani G; Folgori A; Vitelli A; Ruggeri L; Nicosia A; Piccolella E; Del Porto P
    Eur J Immunol; 2005 Sep; 35(9):2627-37. PubMed ID: 16114108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunogenicity and heterologous protection in mice with a recombinant adenoviral-based vaccine carrying a hepatitis C virus truncated NS3 and core fusion protein].
    Guan J; Deng Y; Chen H; Yang Y; Wen B; Tan W
    Bing Du Xue Bao; 2015 Jan; 31(1):7-13. PubMed ID: 25997323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Priming with two DNA vaccines expressing hepatitis C virus NS3 protein targeting dendritic cells elicits superior heterologous protective potential in mice.
    Guan J; Deng Y; Chen H; Yin X; Yang Y; Tan W
    Arch Virol; 2015 Oct; 160(10):2517-24. PubMed ID: 26215441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polyfunctional CD8(+) T cells are associated with the vaccination-induced control of a novel recombinant influenza virus expressing an HCV epitope.
    Tan AC; Eriksson EM; Kedzierska K; Deliyannis G; Valkenburg SA; Zeng W; Jackson DC
    Antiviral Res; 2012 May; 94(2):168-78. PubMed ID: 22504097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance of CD8(+) T-cell memory following infection with recombinant sindbis and vaccinia viruses.
    Villacres MC; Zuo J; Bergmann CC
    Virology; 2000 Apr; 270(1):54-64. PubMed ID: 10772979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.